Designer immunity technologies governance

Introduction

Designer immunity technologies refer to advanced biomedical and biotechnological interventions developed to strengthen, modify, or regulate the human immune system against infectious diseases, environmental threats, and certain medical conditions. These technologies include engineered immune cells, synthetic vaccines, monoclonal antibodies, gene-based immune interventions, immune-modulating drugs, and personalised immunotherapies.

The governance of designer immunity technologies involves establishing legal, ethical, medical, and regulatory standards for their research, development, clinical testing, manufacturing, and commercial use. Since these technologies may directly influence human biological functions, their regulation must address patient safety, informed consent, genetic privacy, equitable access, biosafety, and long-term health consequences.

Meaning and categories of designer immunity technologies

Designer immunity technologies are developed to produce targeted or enhanced immune responses through scientific intervention.

Major categories include:

1. Engineered immune cells: These involve modifying immune cells to recognise and respond to specific diseases. CAR-T cell therapy is an established example of engineered cellular immunotherapy.

2. Synthetic vaccines: These use advanced biological platforms to stimulate immune responses against particular pathogens or disease targets.

3. Monoclonal antibodies: These laboratory-produced antibodies target specific biological molecules and are used in several therapeutic applications.

4. Gene-based immune interventions: These involve genetic techniques intended to modify immune-related biological functions.

5. Personalised immunotherapy: These treatments are developed according to individual biological characteristics, disease conditions, or immune responses.

Each category presents different regulatory requirements depending on its mechanism, intended use, manufacturing process, and potential risks.

Legal framework in India

India does not currently have one comprehensive statute specifically governing all designer immunity technologies. Their regulation is distributed across pharmaceutical, biotechnology, clinical research, environmental, and data protection laws.

1. Drugs and Cosmetics Act, 1940

The Act provides the principal statutory framework for regulating drugs and relevant biological products in India.

Designer immunity products intended for therapeutic use may require compliance with applicable licensing, manufacturing, quality-control, and safety requirements.

2. New Drugs and Clinical Trials Rules, 2019

These Rules establish requirements for new drug approvals, clinical trials, ethics committees, informed consent, and compensation in specified circumstances.

Advanced immunotherapies and other innovative biological treatments may fall within the relevant regulatory framework depending on their classification.

3. Environment (Protection) Act, 1986

The Act and the Rules of 1989 concerning hazardous microorganisms and genetically engineered organisms may apply to research involving regulated genetically engineered organisms or cells.

Relevant institutional biosafety and regulatory approvals must be obtained where required.

4. Biological Diversity Act, 2002

The Act provides a framework for biodiversity conservation, sustainable use, and benefit-sharing.

Its requirements may become relevant when research involves biological resources covered by the legislation, subject to applicable exclusions and statutory provisions.

5. Digital Personal Data Protection Act, 2023

Designer immunity research may involve genetic information, medical histories, clinical trial records, and other sensitive personal information.

Where digital personal data are processed, organisations must comply with applicable requirements concerning lawful processing, security safeguards, and individual rights.

International legal framework

1. World Health Organization guidelines

WHO guidance concerning biological products, vaccine development, and clinical research provides important scientific and regulatory standards. These guidelines support product quality, safety, efficacy, and responsible manufacturing.

2. International Council for Harmonisation (ICH)

ICH guidelines establish internationally recognised technical standards for pharmaceutical development, clinical trials, quality management, and safety evaluation.

Relevant standards include:

ICH E6 on Good Clinical Practice.

ICH Q5A on viral safety evaluation of biotechnology products.

ICH Q9 on quality risk management.

ICH Q10 on pharmaceutical quality systems.

3. UNESCO Universal Declaration on Bioethics and Human Rights, 2005

The declaration promotes human dignity, informed consent, equality, privacy, and social responsibility in biomedical research.

4. Convention on Biological Diversity, 1992

The Convention provides principles concerning biodiversity conservation, sustainable use, and benefit-sharing where biological resources fall within its scope.

Major governance challenges

1. Human safety and clinical risks

Engineered immune therapies may produce unexpected immune responses, inflammatory complications, or other adverse effects. Regulatory authorities must require appropriate preclinical assessment and clinical monitoring.

2. Informed consent

Patients participating in experimental immunotherapy research must understand the treatment's purpose, uncertainties, potential risks, and available alternatives.

3. Genetic privacy

Personalised immune technologies may involve genetic sequencing and extensive medical data. Organisations must establish safeguards against unauthorised access and inappropriate secondary use.

4. Long-term monitoring

Certain cellular and genetic interventions may have long-lasting effects. Appropriate follow-up and adverse-event reporting are therefore important.

5. Unequal access

Advanced immune therapies may be expensive and concentrated in specialised medical institutions. Governments must consider fair access and affordability.

6. Commercialisation and intellectual property

Patent protection may encourage innovation, but exclusive rights and high treatment costs can create difficulties for public healthcare systems.

7. Dual-use concerns

Certain biotechnology research may have both beneficial and potentially harmful applications. Appropriate biosafety and biosecurity oversight is necessary.

Important case laws

Direct Indian judicial decisions specifically concerning designer immunity technologies remain limited. However, the following judgments establish important legal principles relevant to their governance.

1. Samira Kohli v. Dr. Prabha Manchanda (2008) 2 SCC 1

The Supreme Court explained the requirements of informed consent in medical treatment. It held that consent for one medical procedure does not automatically authorise a substantially different procedure.

This judgment is relevant to experimental immune therapies because patients must receive adequate information before undergoing innovative biomedical interventions.

2. Common Cause v. Union of India (2018) 5 SCC 1

The Supreme Court recognised the importance of individual autonomy and dignity in medical decision-making, particularly concerning end-of-life decisions and advance medical directives.

Its principles support the importance of respecting patient autonomy in decisions involving advanced biomedical treatments.

3. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017) 10 SCC 1

The Supreme Court recognised privacy as a fundamental right under Article 21 and other constitutional freedoms.

The judgment is relevant to designer immunity technologies because personalised treatments may require processing genetic information, medical records, and other highly personal data.

4. Novartis AG v. Union of India (2013) 6 SCC 1

The Supreme Court interpreted Section 3(d) of the Patents Act, 1970, and examined the patentability of a pharmaceutical product.

The decision is relevant to designer immunity technologies because it demonstrates that pharmaceutical innovation must satisfy statutory patentability requirements and that incremental modifications do not automatically qualify for patent protection.

5. A.P. Pollution Control Board v. Prof. M.V. Nayudu (1999) 2 SCC 718

The Supreme Court emphasised the importance of scientific expertise in regulatory decision-making involving technical and environmental uncertainty.

Its principles are relevant to evaluating the scientific risks associated with advanced biological technologies.

Regulatory safeguards and governance mechanisms

Effective governance requires coordinated oversight throughout the development and commercialisation of designer immunity technologies.

Important safeguards include:

Independent ethics committee approval for relevant human research.

Evidence-based preclinical and clinical evaluation.

Proper informed consent procedures.

Standardised manufacturing and quality-control requirements.

Long-term monitoring of significant adverse events.

Protection of genetic and medical information.

Transparent reporting of clinical outcomes.

Appropriate biosafety and biosecurity assessments.

Fair access policies for essential therapies.

Regulatory authorities should also establish clear procedures for evaluating innovative cellular and genetic treatments without unnecessarily delaying scientifically justified medical developments.

Conclusion

Designer immunity technologies represent an important development in modern biotechnology and personalised medicine. However, their use raises complex questions concerning patient safety, genetic privacy, informed consent, clinical research, intellectual property, and equitable access. India's pharmaceutical, biotechnology, environmental, and data protection laws provide several regulatory foundations, although no single comprehensive statute governs every designer immunity technology. Judicial decisions concerning medical consent, privacy, pharmaceutical patents, and scientific assessment provide important guidance. Effective governance requires independent scientific evaluation, transparent regulatory procedures, long-term safety monitoring, and respect for individual rights.